BioOutsource Ltd. has opened a new Biosimilar Centre of Excellence in Glasgow, doubling its capacity for the analysis of biosimilar monoclonal antibodies. The new CoE is adjacent to the company’s existing BioOutsource facility on the West of Scotland Science Park, and will employ approximately 40 lab and R&D scientists.
“The global biosimilar market is predicted to more than double in size to $19 billion by 2018. The increasing demand for our biosimilars services and the addition of several new clients has made this a necessary investment for 2014, as our revenues in this market have quadrupled in the last 18 months,” said BioOutsource chief executive officer, Gerry MacKay. “We are delighted to announce the opening of this new, state-of-the-art Biosimilar Centre of Excellence in Glasgow.”
“We are committed to providing our clients with excellent levels of service and technical support,” continued Mr. MacKay. “In 2013 we increased our headcount by 30% as we added new services to our portfolio and we anticipate repeating this expansion in the first quarter of this year. We have now worked with no fewer than 30 global biosimilar companies who use our range of off-the-shelf assays for the comparability, stability and lot release testing of their biosimilars.”